Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Inherited Metabolic Disease

• Publication date

  2008-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10545-008-0848-3PMID 18509742
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy with agalsidase alfa in children with Fabry disease

  2007cited by this paper
• Cardiac MRI: accuracy of simultaneous measurement of left and right ventricular parameters using three different sequences

  2007cited by this paper
• Agalsidase-Beta Therapy for Advanced Fabry Disease

  2007cited by this paper
• Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.

  2006cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006cited by this paper
• The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease

  2006cited by this paper
• Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

  2006cited by this paper
• Clinical benefit of enzyme replacement therapy in Fabry disease.

  2006cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006cited by this paper
• Agalsidase-Beta Therapy for Advanced Fabry Disease A Randomized Trial

  2006cited by this paper
• Prevalence of uncontrolled hypertension in patients with Fabry disease.

  2006cited by this paper
• High incidence of later-onset fabry disease revealed by newborn screening.

  2006cited by this paper
• Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.

  2006cited by this paper
• Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

  2005influential reference
• Thirty‐four novel mutations of the GLA gene in 121 patients with Fabry disease

  2005cited by this paper
• The right ventricle in Fabry disease

  2005cited by this paper
• Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease

  2005cited by this paper
• Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST).

  2005cited by this paper
• Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase A

  2005cited by this paper
• Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.

  2005cited by this paper
• Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.

  2004cited by this paper
• Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

  2004cited by this paper
• Fabry disease: overall effects of agalsidase alfa treatment

  2004cited by this paper
• Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease

  2004influential reference
• Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady‐state free precession imaging sequences

  2003influential reference
• Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease: A Prospective Strain Rate Imaging Study

  2003cited by this paper
• Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course

  2002cited by this paper
• Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients

  2002cited by this paper
• Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

  2002cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

  2001cited by this paper
• New insights in cardiac structural changes in patients with Fabry's disease.

  2000cited by this paper
• Ambulatory blood pressure: normality and comparison with other measurements.

  1999cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit.

  1999cited by this paper
• Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study.

  1999cited by this paper
• Mortality and Morbidity of Aortic Regurgitation in Clinical Practice

  1999cited by this paper
• Ambulatory blood pressure: normality and comparison with other measurements. Hypertension Working Group.

  1999cited by this paper
• A practical guide to assessment of ventricular diastolic function using Doppler echocardiography.

  1996cited by this paper
• Determinants of echocardiographic aortic root size. The Framingham Heart Study.

  1995cited by this paper
• Electrophysiologic findings in Fabry's disease with a short PR interval.

  1994cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993influential reference
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• An atypical variant of Fabry's disease with manifestations confined to the myocardium.

  1991cited by this paper
• Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease

  1990cited by this paper
• Is left ventricular mass in apparently healthy, normotensive men correlated to maximal blood pressure during exercise?

  1990cited by this paper
• New ergometric reference values for clinical exercise tests.

  1990cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper
• Transesophageal echocardiography.

  1989cited by this paper
• Normal limits of the electrocardiogram in a Chinese population.

  1989cited by this paper
• Echocardiographic abnormalities and disease severity in Fabry's disease.

  1986cited by this paper
• Electrocardiograms in Fabry's disease.

  1982cited by this paper
• :A long term follow-up study

  1982cited by this paper
• Cardiac Valvular Anomalies in Fabry Disease: Clinical, Morphologic, and Biochemical Studies

  1976cited by this paper

• Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down‐Regulation of Mannose‐6‐Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy

  2025cites this paper
• A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta

  2025cites this paper
• Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?

  2024cites this paper
• Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation and Down-Regulation of Mannose6Phosphate Receptors cause Low accessibility to Enzyme Replacement Therapy

  2023cites this paper
• Cardiac involvement in Fabry disease - A non-invasive assessment and the role of specific therapies.

  2022cites this paper
• Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation

  2022cites this paper
• The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

  2019cites this paper
• The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease.

  2019cites this paper
• Anderson-Fabry disease in heart failure

  2018cites this paper
• Early markers of heart and kidney damage in Fabry disease

  2018influential citation
• Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease

  2018cites this paper
• Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review

  2018cites this paper
• Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies

  2017cites this paper
• Enzyme replacement therapy in Fabry disease, towards individualized treatment

  2017cites this paper
• Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies

  2017cites this paper
• Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation

  2016cites this paper
• Pharmacological Chaperones as Potential Therapeutics for Lysosomal Storage Disorders: Preclinical Research to Clinical Studies

  2016cites this paper
• Quality of life in patients with Fabry disease: a systematic review of the literature

  2015cites this paper
• Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

  2014cites this paper
• Treatment of lysosomal storage diseases: recent patents and future strategies.

  2014cites this paper
• Systematic review of the statistical scope used in studies based on skeletal muscle autophagy and exercise

  2014cites this paper
• Pharmacological chaperones as therapeutics for lysosomal storage diseases.

  2013cites this paper
• Renal Transplantation in Patient with Fabry’s Disease Maintained by Enzyme Replacement Therapy

  2012cites this paper
• Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Münster Study (FaMüS) data

  2012cites this paper
• Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

  2012cites this paper
• Enzyme replacement therapy improves cardiac features and severity of Fabry disease.

  2012cites this paper
• Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

  2012cites this paper
• Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease

  2012cites this paper
• Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease

  2012cites this paper
• Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

  2011cites this paper
• Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy

  2011cites this paper
• Anderson-Fabry disease: a cardiomyopathy that can be cured.

  2011cites this paper
• Echocardiographic assessment of fabry cardiomyopathy: early diagnosis and follow-up.

  2011cites this paper
• Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature

  2010cites this paper
• Anderson-Fabry disease and the heart.

  2010cites this paper
• Agalsidase Beta Clinical Trials and Long Term Experience

  2010cites this paper
• Analyses of Agalsidase Alfa and Agalsidase Beta for the Treatment of Fabry Disease

  2010cites this paper
• Potential Factors Influencing Treatment Outcomes

  2010cites this paper
• Fabry disease

  2010cites this paper
• Cardiopulmonary involvement in Fabry’s disease

  2010cites this paper
• Fabry disease: a review of current management strategies.

  2010cites this paper
• Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.

  2010cites this paper
• Evaluating enzyme replacement therapy in fabry disease.

  2010cites this paper
• Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy

  2009cites this paper
• Effects of enzyme-replacement therapy in patients with Anderson–Fabry disease: a prospective long-term cardiac magnetic resonance imaging study

  2009cites this paper
• Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

  2009cites this paper
• Current World Literature

  2009cites this paper
• Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring

  2009cites this paper
• Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and dose.

  2008cites this paper
• Lysosomes

  1966cites this paper